AGN Allergan Plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands andbest-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.
Company profile
Ticker
AGN
Exchange
Website
CEO
Brenton L. Saunders
Employees
Incorporated in
Location
Fiscal year end
Industry (SEC)
Former names
Actavis Ltd, Actavis plc
SEC CIK
Corporate docs
AGN stock data
()
Calendar
7 May 20
11 Jul 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | 4.35B | 4.05B | 4.09B | 3.6B | |
| Net income | -317.2M | -786.8M | -1.76B | -2.41B | |
| Diluted EPS | -0.97 | -2.4 | -5.37 | -7.25 | |
| Net profit margin | -7.29% | -19.42% | -43.01% | -66.94% | |
| Operating income | -276.6M | -596.6M | -1.26B | -2.31B | |
| Net change in cash | 1.27B | -413.9M | 862.9M | -91.9M | |
| Cash on hand | 2.5B | 1.24B | 1.65B | 788.5M | |
| Cost of revenue | 704M | 639M | 652.3M | 497.8M |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | 16.09B | 15.79B | 15.94B | 14.57B | |
| Net income | -5.27B | -5.1B | -4.13B | 14.97B | |
| Diluted EPS | -16.02 | -15.26 | -13.19 | 38.18 | |
| Net profit margin | -32.76% | -32.28% | -25.88% | 103% | |
| Operating income | -4.45B | -6.25B | -5.92B | -1.83B | |
| Net change in cash | 1.62B | -936.8M | 93.2M | 628M | |
| Cash on hand | 2.5B | 880.4M | 1.82B | 1.72B | |
| Cost of revenue | 2.49B | 2.19B | 2.17B | 1.86B |
Financial data from Allergan earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 8 May 20 | McDonnell Peter J | Ordinary Shares, par value $0.0001 | Sale back to company | Dispose D | No | 0 | 6,352 | 0 | 0 |
| 8 May 20 | Coughlin Christopher J | Ordinary Shares, par value $0.0001 | Sale back to company | Dispose D | No | 0 | 16,532 | 0 | 0 |
| 8 May 20 | Coughlin Christopher J | Ordinary Shares, par value $0.0001 | Sale back to company | Dispose D | No | 0 | 471 | 0 | 26,080 |
| 8 May 20 | Coughlin Christopher J | Stock Options Ordinary Shares | Sale back to company | Dispose D | No | 70.79 | 9,446 | 668.68K | 0 |
| 8 May 20 | Coughlin Christopher J | Stock Options Ordinary Shares | Sale back to company | Dispose D | No | 73.14 | 3,691 | 269.96K | 0 |
| 8 May 20 | Coughlin Christopher J | Stock Options Ordinary Shares | Sale back to company | Dispose D | No | 90.22 | 2,790 | 251.71K | 0 |
| 8 May 20 | William Meury | RSU | Sale back to company | Dispose D | No | 0 | 25,201 | 0 | 0 |
| 8 May 20 | William Meury | Ordinary Shares, par value $0.0001 | Sale back to company | Dispose D | No | 0 | 7,434 | 0 | 0 |
| 8 May 20 | William Meury | Performance Stock Units Ordinary Shares | Sale back to company | Dispose D | No | 0 | 26,506 | 0 | 0 |
| 8 May 20 | William Meury | Stock Options Ordinary Shares | Sale back to company | Dispose D | No | 196.16 | 12,304 | 2.41M | 0 |
Institutional ownership Q1 2020
87.7% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 849 |
| Opened positions | 80 |
| Closed positions | 156 |
| Increased positions | 272 |
| Reduced positions | 362 |
13F shares |
Current |
|---|---|
| Total value | 50.96B |
| Total shares | 287.78M |
| Total puts | 5.69M |
| Total calls | 1.18M |
| Total put/call ratio | 4.8 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 25.15M | $4.45B |
| BLK BlackRock | 21.14M | $3.74B |
| STT State Street | 13.7M | $2.43B |
| CS Credit Suisse | 10.73M | $1.9B |
| Adage Capital Partners GP, L.L.C. | 9.37M | $1.66B |
| Farallon Capital Management | 9.3M | $1.65B |
| BAC Bank of America | 8.43M | $1.49B |
| C Citigroup | 7.93M | $1.4B |
| GS The Goldman Sachs Group, Inc. | 7.49M | $1.33B |
| Renaissance Technologies | 7.09M | $1.26B |
Financial report summary
?Competition
Akorn • TherapeuticsMD • Amgen • Insite Vision • Medicis Pharmaceutical • Hologic • Veru • VIVUS • Cynosure • Uroplasty
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
alpha, API, argument, Asia, AstraZeneca, autoimmune, behavior, biodegradable, broadest, built, buyer, Cadila, certainty, chain, composition, confirm, confirming, contamination, continent, Coolsculpting, CoolTone, Cream, cystic, declare, deliver, detailing, discontinuation, discontinued, distancing, Durysta, electronic, enrolling, environment, enzyme, Esthetique, evolve, exocrine, experienced, Gedeon, genericization, glaucoma, globe, half, home, hypertension, inability, indirectly, inhibitor, innovation, insufficiency, intracameral, intraocular, IOP, Ireland, Lab, Lazeo, LIBOR, lifetime, local, logistical, losing, medial, minute, mitigate, Nestle, OAG, ocular, OHT, outbreak, Pacific, pancreatic, pandemic, patient, pressure, rebate, recession, recovery, relationship, remotely, reply, Richter, satisfaction, Science, shelter, spent, spread, strain, susceptible, suspended, temporarily, Ubrelvy, unemployment, Viokace, Vital
Removed:
absence, acceleration, acid, add, adjunctive, advancement, affirming, Akorn, Akron, Apotex, appellate, applied, Argentum, asserting, authorize, automatically, back, binding, BioMed, Biomedical, Body, bound, buy, calculate, calculated, capitalized, capitalizing, Center, centralized, certiorari, chosen, clarify, cloud, collateralization, collateralized, commonly, computing, concurrently, Contouring, contractually, conversion, correct, corrected, Corrupt, cumulative, delaying, Delzicol, denial, denying, Depressive, dermatology, determining, Deva, disgorgement, Disorder, dozen, Easement, enablement, enacted, enforceable, Envy, equaled, equipment, equitable, error, established, estate, Europe, exemption, exercised, expedient, explicitly, Famy, fiscal, fleet, fourth, Framework, gamma, GILTI, ground, Harbor, HD, higher, hosted, immunity, implementation, implicit, implicitly, improper, incorrectly, India, Influenced, InnoPharma, institute, instrument, intent, invalidity, inventorship, issuing, joinder, LA, land, lease, leasing, Legacy, legally, lessee, lessor, Lidoderm, LifeCell, limit, Low, mandatorily, mandatory, MDD, modified, modify, noncancelable, notification, offsetting, older, opening, option, orphan, ownership, package, pattern, Pennsylvania, pension, permission, pertaining, Pharmacal, pivotal, plant, Plastic, postretirement, practical, preferred, prepaid, preventing, privately, pronouncement, prospectively, purpose, qualify, Racketeer, rapastinel, rating, reaching, real, receptor, reclassification, reclassify, recognition, redeemed, refinancing, released, remove, renew, renewal, rental, Replacement, represented, requiring, residual, restitution, resurfacing, retinoic, retired, retrospective, retrospectively, revaluation, reversing, RORyt, ROU, SA, scaling, shortened, skin, Slayback, software, sovereign, standalone, statutory, stranded, substantive, substitute, Subtopic, suit, supplier, Surgery, suspension, Targeted, Taxed, TCJA, terminate, Therapy, threshold, topline, treble, tribal, TWi, Ubrogepant, unrelated, updated, USD, vendor, VI, Vitae, withdraw, withdrew, writ
Financial reports
10-Q
2020 Q1
Quarterly report
7 May 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
10-K
2019 FY
Annual report
18 Feb 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
15 Feb 19
10-Q
2018 Q3
Quarterly report
31 Oct 18
10-Q
2018 Q2
Quarterly report
3 Aug 18
10-Q/A
2018 Q1
Quarterly report (amended)
25 May 18
Current reports
8-K
Material Modifications to Rights of Security Holders
14 May 20
8-K
AbbVie Inc. Completes Acquisition of Allergan plc
8 May 20
8-K
Announcement relating to the outcome of the Court Sanction Hearing
6 May 20
8-K
Temporary Suspension of Trading Under Registrant's Employee Benefit Plans
21 Apr 20
8-K
AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction
18 Mar 20
8-K
AbbVie and Allergan Receive Final European Approval to Close Pending Transaction
3 Mar 20
8-K
Allergan Reports Fourth Quarter and Full-Year 2019 Financial Results
10 Feb 20
8-K
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
27 Jan 20
8-K
Third Quarter 2019 Financial Results—Frequently Asked Questions
5 Nov 19
8-K
Allergan Reports Third Quarter 2019 Financial Results
5 Nov 19
Registration and prospectus
15-12B
Securities registration termination
21 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
Proxies
DEFA14A
Additional proxy soliciting materials
3 Oct 19
DEFA14A
Additional proxy soliciting materials
27 Sep 19
DEFM14A
Proxy related to merger
16 Sep 19
DEFA14A
Additional proxy soliciting materials
11 Sep 19
PREM14A
Preliminary proxy related to merger
12 Aug 19
DEFA14A
Additional proxy soliciting materials
12 Jul 19
DEFA14A
Additional proxy soliciting materials
8 Jul 19
DEFA14A
Additional proxy soliciting materials
2 Jul 19
DEFA14A
Additional proxy soliciting materials
28 Jun 19
DEFA14A
Additional proxy soliciting materials
28 Jun 19
Other
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
SD
Conflict minerals disclosure
23 May 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
UPLOAD
Letter from SEC
23 Feb 17
CORRESP
Correspondence with SEC
14 Feb 17
UPLOAD
Letter from SEC
7 Feb 17
Ownership
4
Allergan / Nesli Basgoz ownership change
12 May 20
4
Allergan / Joseph H Boccuzi ownership change
12 May 20
4
Allergan / ROBERT J HUGIN ownership change
12 May 20
4
Allergan / CHRIS W BODINE ownership change
12 May 20
4
Allergan / James DArecca ownership change
12 May 20
4
Allergan / Adriane M Brown ownership change
12 May 20
4
Allergan / A Robert D Bailey ownership change
12 May 20
4
Allergan / THOMAS C FREYMAN ownership change
12 May 20
4
Allergan / MATTHEW M WALSH ownership change
12 May 20
4
Allergan / CAROL ANTHONY DAVIDSON ownership change
12 May 20
Patents
APP
Utility
Process of Making Cenicriviroc and Related Analogs
9 Jul 20
The disclosure includes high purity compounds having CCR5 and/or CCR2 antagonism, or a salt thereof, and processes for synthesizing the same.
GRANT
Utility
Stable formulations of linaclotide
7 Jul 20
The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
GRANT
Utility
Gene silencing in skin using self-delivery siRNA delivered by a meso device
30 Jun 20
The present invention is drawn to a low-cost “meso” device that is able to effectively deliver functional self-delivery siRNA to subject and inhibit expression of a gene in the subject as well as related methods.
GRANT
Utility
5-aminosalicylic acid capsule formulation
23 Jun 20
A dosage form comprising a capsule containing one or more tablets of 5-aminosalicylic acid or a salt thereof as an active ingredient where each of the one or more tablets is enterically coated is disclosed.
APP
Utility
Formulations of Deoxycholic Acid and Salts Thereof
18 Jun 20
The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate.